Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (R21 Clinical Trial Optional)

Funding Opportunity PAR-18-606 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages transdisciplinary research that will leverage cognitive neuroscience to improve traditional measurement of cognitive impairment following cancer treatment, often referred to as chemobrain. A better understanding of the acute- and late-term cognitive changes following exposure to adjuvant chemotherapy and molecularly-targeted treatments, including hormonal therapy, for non-central nervous system tumors can inform clinical assessment protocols with downstream implications for survivorship care plans.

from NIH Funding Opportunities (Notices, PA, RFA) http://ift.tt/2DKRgq5